AeroVironment's Record Backlog and Earnings Beat Strengthen Demand Case, but Execution Risks Persist

What happened

AeroVironment reported Q1 funded backlog of $1.5 billion, up 37% year over year, and total backlog of $2.8 billion, along with an earnings beat according to MarketBeat. This marks a substantial increase from the $1.18 billion funded backlog at the end of fiscal 2026 and supports management's FY27 revenue guidance of $2.125-$2.225 billion. The DeepValue master report had already recognized strong demand in loitering munitions and counter-UAS, but it flagged execution concerns including a 32% Q4 gross margin, a $240.7 million goodwill impairment, and ineffective internal controls. While the backlog growth reduces near-term revenue conversion risk, it does not address the margin compression or the material weaknesses in financial reporting that weighed on the prior thesis. Consequently, the news is directionally positive but insufficient to warrant a rating change from WAIT without evidence of improved profitability and control remediation.

Implication

The stronger backlog and earnings beat increase confidence that FY27 revenue will track the upper end of guidance, but the company still needs to prove it can convert orders into profitable growth. Investors should monitor whether the next quarterly filing shows gross margin recovering above 34% and any progress on remediating the material weaknesses in internal controls. Until then, the attractive entry level remains near $145, and trim level near $190, as the current price likely still embeds some execution optimism. The risk-reward is improving but not yet compelling enough for fresh buying; a move above $190 without evidence of margin expansion would signal overvaluation. Patience is warranted, with key catalysts being the next earnings release and the 10-Q filing for signs of control remediation and margin stabilization.

Thesis delta

The demand side of the thesis has strengthened with record backlog and an earnings beat, reducing the probability of a revenue shortfall in FY27. However, the core concerns around gross margin pressure, SCDE profitability, and internal control weaknesses remain unaddressed by this news. Therefore, the overall thesis is unchanged: WAIT, with a slightly higher conviction in the base case but no rating change until execution quality improves.